http://www.nccn.net/~wwithin/conflict.htm
Conflict
of Interest Information - Drug Companies, CDC, FDA, Doctors, $$$$
Any
information obtained here is not to be construed as medical or legal advice.
The decision to vaccinate and how you implement that decision is yours and
yours alone.
Congressman Burton
critical of Vaccine Approval Process
Staff Report detailing
conflicts of interest
Info on Samuel
Katz, MD who was featured on 60 minutes MMR/Autism Segment 11/12/2000
http://www.abcnews.go.com/sections/living/SecondOpinion/secondopinion_53.html
Also
testifies AGAINST vaccine damaged children
Also one
of the developers of measles vaccine and involved deeply with the vaccine
industry
More
conflict of interest links
Merck's Quiet Effort
Merck paid legislators, hospitals, docs and organizations!
4/16/200 Akron (Ohio) Beacon Journal
Merck's quiet effort
Vaccine maker backs legislation
Adm.
William J. Crowe Jr. is the most visible corporate director of the Bioport Corp.,
which manufactures the anthrax vaccine. http://www.abcnews.go.com/onair/2020/2020_990312_anthrax_feature.html
War on Truth:
The Secret Battle for the American Mind
Proposed
Research Misconduct Policy Discussed
Rezulin
Dangers Withheld
"The FDA is reviewing accusations that the manufacturer of the diabetes
drug Rezulin withheld evidence of liver toxicity from the agency until six
months after Rezulin was marketed. A spokeswoman for the agency said it would
look into accusations by Public Citizen's Health Research Group, a patient
advocacy group, that Rezulin's maker delayed telling the FDA that 21 patients
had developed liver abnormalities while taking the drug before it was approved.
Federal regulations require that drug companies report adverse drug reactions
to the drug agency within 15 days of learning about them. In a March 14 letter
to the agency, Public Citizen requested a criminal investigation of the
manufacturer, Parke-Davis, division of the Warner-Lambert Company of Morris
Plains, NJ"
Editorial
Reply Re: Congressional Hearings on Vaccines and Autism
Mandating
Vaccines: Government Practicing Medicine Without a License?
From: Dawn
Richardson, PROVE
This is a
phenomenal letter written by a parent of a vaccine injured child in response to
an editorial comment published on WebMD. It clearly illustrates the incestuous
ties some of those who make vaccine decisions for our children have with drug
companies. These are the very people who are critical of the parents and
elected representatives who are doing such a great job shedding light on some
of the dangers of vaccines because of the threat the truth poses to their
pocketbooks. The internet (source of all this information) is a wonderful
thing.
-----------------------------------------
In Reply to Editorial Comment from: Wayne L. Pines Re: Congressional Hearings
on Vaccines and Autism
Wayne L. Pines,
you belittle Congressman Burton as an "angry grandfather" when his
goal is to make vaccines safer for children. Your feeble attempt to undermine
Congressman Burton's efforts made sense only after your ties to the vaccine
manufacturers and drug companies were revealed. This is a day in your life
Wayne L. Pines. Let's see who you really are and then people will understand
that your words are meaningless because they are motivated by avarice.
You started your
career in Washington as the associate editor for The Pink Sheet a
pharmaceutical trade magazine. Then you went to work at the FDA for 10 years
from 1972 to 1982. Your next job was with the PR firm Burson-Marsteller. After
that, you got a job with APCO Associates. Then you joined a company called
Therametrix (1). In between you became involved with various pharmaceutical
trade groups such as the Food and Drug Law Institute (2), the Drug Information
Association (3), and the Internet Healthcare Coalition (4).
Now let's start
connecting the dots to see why you would not want a public discussion about how
to improve the safety of our children's vaccines. We'll pick-up your career
after you leave the FDA. You immediately landed a job with the PR firm
Burson-Marsteller (a subsidiary of the advertising agency Young & Rubicam).
Your title there was executive vice president. Marsteller clients include
Monsanto and their bio-engineered foods and Dow-Corning and their silicon
breast implants. In addition, Marsteller has several large drug companies as
clients including Eli Lilly. Lilly produces the drug Prozac which has
accumulated more adverse reaction reports than any substance (besides vaccines)
in the history of the FDA's adverse drug reporting system. Documents released
under the Freedom of Information Act challenged the veracity of Prozac's
clinical trials that led to FDA approval. Lilly's PR firm Burson-Marsteller was
called in to do damage control. There, according to the Campaign Against
Fraudulent Medical Research, it was reported that you helped Lilly get past its
troubles by exploiting your contacts with current FDA officials (5).
You then became
president of the Health Care Practice of APCO Associates a "communications
consulting firm." According to PR Watch, APCO Associates specializes in
setting up front groups and coalitions for the tobacco and insurance companies
(6). In fact, APCO's website boasts that "excellence in public affairs and
public relations, like excellence in art, is about the power of
communication" (7). No it's not. Excellence in public affairs is about
honest communication and adding substance to the public discourse. It's what
Congressman Burton is doing. It's not about ridiculous, crude and poorly veiled
attempts to protect and further your client base. You may think excellence in
public affairs and public relations is about power, but power won't help you
when it comes to our children. As much as it may disturb your plans, parents
will not sacrifice the health and lives of their children in order to drive up
the stock prices of your drug company clients.
Next you joined
Therametrix whose website gloats that "Wayne L. Pines is a world-renowned
health care consultant (who) has consulted for virtually all of the major
pharmaceutical companies..."(1). It also states that Therametrix is a
"medical marketing research agency that serves the pharmaceutical,
biotechnology, medical device and consumer health products industries"
(8). Your clients are listed as including: Abbot Laboratories, Bayer,
Bristol-Myers Squibb, Du Pont Pharmaceuticals, Eli Lilly, Glaxo Wellcome,
Novartis Pharmaceuticals, Pharacia & Upjohn, Procter & Gamble
Pharmaceuticals, Roche Laboratories, Schering-Plough, Triangle Pharmaceuticals
and Warner Lambert - all of them drug and vaccine manufacturers (9). Your
company's mission statement declares, "We see nothing more important than
meeting our client's needs" (9). I don't doubt it.
You are also on
the marketing and advertising committee of the Drug Information Association
which describes itself as a "member-driven scientific association with a
membership of over 22,000 primarily from the regulatory agencies, academia,
contract service organizations, pharmaceutical, biological and device industry,
and from other health care organizations" (10). Who are some of the other
committee members in the Drug Information Association? They include Dr. R.
Venkataraghaven of Lederle Laboratories (3) manufacturer of Orimune, Tetramune
and other vaccines, Dr. Elizabeth B. D'Angelo of AstraZeneca (3), and Dr. John
F. Bedard of Bristol-Myers Squibb (3). The board of directors include Stuart W.
Cummings of Merck, Sharp & Dohme manufacturer of the vaccines associated
with autism - MMR, MR Vax, Meruvax II, Mumpsvax, Varivax and others, Francoise
de Cremiers of Wyeth-Ayerst another major vaccine manufacturer, Charles C. Depew
of SmithKline Beecham, Brenton James of Glaxo Wellcome, Murray Lumpkin of the
FDA, and Irwin G. Martin of Parke-Davis (11).
In addition, you
are a member of the Food and Drug Law Institute which describes itself "as
a private organization, not affiliated with the FDA.(but our) mission, however,
does relate to the activities, policies and procedures of the FDA..."(12).
As a participant in this institute you work with the other members, and in
fact, you are scheduled to moderate one of the institute's conferences on
medical technology, drugs and biologics (i.e. vaccines) in June of this year
(2). Nearly every drug company including the major vaccine manufacturers is a
member of this organization. The list includes: American Home Products (i.e.
Lederle), Bayer, Medeva Pharmaceuticals, Merck & Co., Organon Teknika, and
SmithKline Beecham.
I could go on and
on about your affiliations with vaccine manufacturers and drug companies but I
believe the point has been made ad nauseam.
One of
Congressman Burton's assertions is that an inherent conflict of interest may
exist amongst the people who decide what gets injected into our children's
veins. The Congressman understands that many of the individuals in our halls of
government who make health decisions affecting our children get money from the
very drug companies they are supposed to be regulating. During the hearings,
when Coleen Boyle of the CDC was asked if she thought there was anything wrong
with such a conflict she was literally speechless. Wayne L. Pines your behavior
is a text book example of what Congressman Burton and tens of thousands of
parents disdain.
As a former
employee of the FDA you use your clout to influence what should be a
scientifically sound, reasonable and objective decision making process. But
even with all of your industry's money and consultants and PR firms and
communication experts and doctors on payrolls you are still missing one key
ingredient - the truth. The truth can't be bought, spun, manipulated, or turned
into a sound bite. Parents know the truth when they watch their children become
ill, disabled and die. So despite your supreme efforts to sell more vaccines,
we will not allow some greedy industry to decide what is safe and to dictate to
us what should be put into our children's bodies.
Wayne L. Pines go
back to your "medical marketing research agency" and your
"communications consulting firm," shut up, and leave our children
alone.
Sincerely,
Michael Horwin
Father of Alexander - a vaccine injured child who passed away at the age of 2 ½
years old
Footnotes:
1) http://www.therametrix.com/staff.html:
http://www.therametrix.com/wayne.html:
2) http://www.fdli.org/conf/medsymagd.htm:
3) http://www.diahome.org/dhp2d12.htm:
4) http://www.ihealthcoalition.org/content/fda_1.html:
5) http://www.pnc.com.au/~cafmr/newsl/prozac.html:
6) http://www.prwatch.org/prw_issues/1996-Q3/index.html:
7) http://www.apcoassoc.com/gallery/gallery.html:
8) http://www.therametrix.com/company.html:
9) http://www.therametrix.com/clients.html:
10) http://www.diahome.org/:
11) http://www.diahome.org/dhp2c.htm:
12) http://www.fdli.org/about/index.html:
CDC misled Congress on spending -
Records show agency diverted funding, filed false reports
Dr Marcia Angell,
former editor of the New England Journal of Medicine, was interviewed. She says
many significant things, but note this in particular as the core of it:
"It used to
be that drug companies simply gave grants to academic medical centres for the
use of their clinical researchers to do a study and that was it. It was at
arm's length. The researcher did a study and he or she published the results,
whatever those results would be. Now, it's very, very different. The drug
companies increasingly design the studies. They keep the data. They don't even
let the researchers see the data. They analyse the data. They decide whether
they're going to even publish the data at the end of it. They sign contracts
with researchers and with academic medical centres saying that they don't get
to publish their work unless they get permission from the drug company. So, you
can see that the distortion starts even before publication. It starts in
determining what's going to be published and what isn't going to be published.
This is no longer arm's length. It's treating the researchers and the academic
medical centres as though they were hired guns or technicians or something.
They just do the work. And the drug company will decide what the data show,
what the conclusions are and whether it will even be published."
Policies
About Physician Interactions With Drug Companies Needed
Critique
of Government-Funded Epidemiology Harris Coulter
Medical Control,
Medical Corruption
Financial
Support to the Immunization Action Coalition
Deborah L. Wexler, MD
Executive Director
Immunization Action Coalition
**publisher of NEEDLE TIPS, VACCINATE ADULTS! and IAC EXPRESS**
1573 Selby Avenue, Suite 234
St. Paul, MN 55104
Phone: (651) 647-9009
Fax: (651) 647-9131
E-mail: deborah@immunize.org
http://www.immunize.org/
IAC EXPRESS: http://www.immunize.org/express/
-------------------------------------------------------------
Groups That Provide Financial Support to the Immunization Action Coalition in
1999
During 1999 the
following groups provided funds to IAC: Government:
Centers for Disease Control and Prevention
Private Sources:
Approximately two thousand private individuals
Professional
Organizations:
American Pharmaceutical Association
Corporations:
Chiron Corporation
GlaxoWellcome
Merck & Co.
Nabi
North American Vaccine
Pasteur Merieux Connaught
SmithKline Beecham
Wyeth Lederle Vaccines
The
New England Journal of Medicine has a policy of disclosing authors' conflicts
of interest, but sometimes the conflicts are too long to print! Here are the
conflicts for just one article in the current issue where the authors are all
academics.
http://www.nejm.org/content/2000/0342/0020/1462.asp
Supported by
Bristol-Myers Squibb. Dr. Keller has served as a consultant to or received
honorariums from Pfizer, Bristol-Myers Squibb, Forest Laboratories/Parke-Davis,
Wyeth - Ayerst, Merck, Janssen, Eli Lilly, Organon, and Pharmacia - Upjohn. He
has received research grants from Wyeth - Ayerst, SmithKline Beecham, Upjohn,
Pfizer, Bristol-Myers Squibb, Merck, Forest Laboratories, Zeneca, and Organon.
He has served on the advisory board of Wyeth - Ayerst, Pfizer, Bristol-Myers
Squibb, Eli Lilly, Forest Laboratories/Parke-Davis, Organon, SmithKline
Beecham, Merck, Janssen, Mitsubishi Pharmaceuticals, Zeneca, Scirex, and
Otsuka. Dr. Klein has served as a consultant to Bristol-Myers Squibb. Dr.
Dunner has served as a consultant to Bristol-Myers Squibb, SmithKline Beecham,
Glaxo Wellcome, and Eli Lilly. He has received research grants from
Bristol-Myers Squibb, Pfizer, Pharmacia - Upjohn, SmithKline Beecham, Forest
Laboratories, Glaxo Wellcome, and Wyeth - Ayerst. He has received speaker's
honorariums from Bristol-Myers Squibb, SmithKline Beecham, Glaxo Wellcome, Eli
Lilly, Organon, and Wyeth - Ayerst. Dr. Gelenberg has received grants and
research support from Bristol-Myers Squibb, Organon, Pfizer, Lilly Research
Laboratories, Janssen, Merck Sharp Dohme, SmithKline Beecham, Wyeth - Ayerst,
Hoechst Marion Roussel, and Forest Laboratories. He has been a member of
speakers' bureaus sponsored by Bristol-Myers Squibb, Pfizer, SmithKline
Beecham, Janssen, Lilly, Forest Laboratories, and Parke-Davis. He is a
stockholder or has other ownership interest in Pfizer, Warner-Lambert, and Eli
Lilly. He has served as a consultant to Eli Lilly, Scios, Forest Laboratories,
Parke-Davis, Pfizer, Janus Pharmaceuticals, Best Practice, and Bristol-Myers
Squibb. Dr. Markowitz has received speaker's honorariums from Bristol-Myers
Squibb, Eli Lilly, Forest Laboratories, Organon, and Pfizer. Dr. Nemeroff has
been a consultant to or received honorariums from Abbott, AstraZeneca,
Bristol-Myers Squibb, Forest Laboratories, Janssen, Eli Lilly, Merck,
Mitsubishi, Neurocrine Biosciences, Organon, Otsuka, Pfizer, Pharmacia -
Upjohn, Sanofi, SmithKline Beecham, Solvay, and Wyeth - Ayerst. He has received
research support from Abbott, AstraZeneca, Bristol-Myers Squibb, Forest
Laboratories, Janssen, Eli Lilly, Organon, Pfizer, Pharmacia - Upjohn,
SmithKline Beecham, Solvay, and Wyeth - Ayerst. Dr. Russell has been a
consultant to or received honorariums from Abbott, Bristol-Myers Squibb,
Janssen, Eli Lilly, Pfizer, and Quintiles. He has received research support
from Abbott, Bristol-Myers Squibb, Eli Lilly, Parke-Davis, Pharmacia - Upjohn,
Pfizer, SmithKline Beecham, Wyeth - Ayerst, Shire, and Quintiles. Dr. Thase has
served as a consultant to Bristol-Myers Squibb, Eli Lilly, Forest Laboratories,
Glaxo Wellcome/Cerenex Pharmaceuticals, Merck, Organon, Pfizer, Pharmacia -
Upjohn, and Wyeth - Ayerst. He has received grant and research support from
Bristol-Myers Squibb, Lipha Pharmaceuticals, Merck, Organon, Pharmacia -
Upjohn, and Wyeth - Ayerst. He has been a member of speakers' bureaus sponsored
by Bristol-Myers Squibb, Eli Lilly, Forest Pharmaceuticals, Glaxo
Wellcome/Cerenex Pharmaceuticals, Organon, Parke-Davis, Pfizer, Pharmacia -
Upjohn, SmithKline Beecham, Solvay, and Wyeth - Ayerst. Dr. Trivedi has
received research grants from Abbott, Akzo (Organon), Bayer, Bristol-Myers Squibb,
Eli Lilly, Forest Laboratories, Glaxo Wellcome, Janssen, Johnson & Johnson,
MeadJohnson, Parke-Davis, Pfizer, Pharmacia - Upjohn, Solvay, and Wyeth -
Ayerst. He has been a member of speakers' bureaus sponsored by Bristol-Myers
Squibb, Forest Laboratories, Pharmacia - Upjohn, Solvay, and Wyeth - Ayerst.
Dr. Zajecka has received grants and research support from Abbott, Bristol-Myers
Squibb, Eli Lilly, Glaxo Wellcome, Organon, Otsuka America, Parke-Davis,
Pfizer, Pharmacia - Upjohn, and Sanofi Research. He has served as a consultant
to or has served on the advisory board of Abbott, Bristol-Myers Squibb, and Eli
Lilly. He has been a member of speakers' bureaus sponsored by Abbott,
Bristol-Myers Squibb, Eli Lilly, Pfizer/Roerig, SmithKline Beecham, Upjohn, and
Wyeth - Ayerst. Dr. Blalock has served as a consultant to Bristol-Myers Squibb.
Dr. DeBattista has been a member of speakers' bureaus sponsored by Abbott,
Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Glaxo Wellcome,
Parke-Davis, Pfizer, Scios, SmithKline Beecham, Wyeth - Ayerst, and Organon. He
has received grants and research support from Abbott, Bristol-Myers Squibb, Eli
Lilly, Forest Laboratories, Glaxo Wellcome, Pfizer, the National Alliance for
Research on Schizophrenia and Depression, Pharmacia - Upjohn, PharmaPrint/ABA,
SmithKline Beecham, and Wyeth - Ayerst. He has served as a consultant to
Bristol-Myers Squibb, Eli Lilly, Glaxo Wellcome, and PharmaPrint. Dr. Fawcett
has received grants and research support from Abbott, Bristol-Myers Squibb,
Glaxo, Eli Lilly, Organon, Pfizer, SmithKline Beecham, Wyeth - Ayerst, and
Zeneca. He has served as a consultant to Abbott, Bristol-Myers Squibb, Eli
Lilly, EM Industries, Forest Laboratories, Glaxo Wellcome, Pfizer, Pharmacia -
Upjohn, and SmithKline Beecham. He has been a member of speakers' bureaus
sponsored by Abbott, Bristol-Myers Squibb, Eli Lilly, Pfizer/Roerig, Pharmacia
- Upjohn, SmithKline Beecham, and Wyeth - Ayerst. Dr. Hirschfeld has received
grants and research support from Abbott, Bristol-Myers Squibb, Organon, and
Pfizer. He has served as a consultant to or on the advisory board of Abbott,
Bristol-Myers Squibb, Glaxo Wellcome, Forest Laboratories, Eli Lilly, Pfizer,
SmithKline Beecham, Janssen, Organon, Parke-Davis, and Pharmacia - Upjohn. Dr.
Kocsis has had research contracts with Bristol-Myers Squibb, Pfizer, Forest
Laboratories, Eli Lilly, and Wyeth - Ayerst. He has received speaker's
honorariums from Bristol-Myers Squibb, Forest Laboratories, and Eli Lilly. He
owns stock in Pfizer and Forest Laboratories. Dr. Kornstein has received
research grants from Bristol-Myers Squibb, Pfizer, Eli Lilly, Glaxo Wellcome,
Forest Laboratories, Mitsubishi Pharmaceuticals, and Biovail. She has served as
a consultant to Bristol-Myers Squibb, Pfizer, Eli Lilly, and Pharmacia -
Upjohn. She has received honorariums from Bristol-Myers Squibb, Pfizer, and
Glaxo Wellcome. Dr. Ninan has received grants and research support from Abbott,
Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Organon, Pharmacia - Upjohn,
SmithKline Beecham, and Solvay. He has served as a consultant to Pfizer,
TAPPharma, and Wyeth - Ayerst. He has been a member of speakers' bureaus
sponsored by Abbott, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories,
Organon, Parke-Davis, Pfizer, Pharmacia - Upjohn, SmithKline Beecham, Solvay,
Janssen, and Wyeth - Ayerst. Dr. Rothbaum has served as a consultant to
Bristol-Myers Squibb and Pfizer. She has been a member of the advisory board of
and a speakers' bureau sponsored by Pfizer. Dr. Rush has received grants and
research support from Abbott, Bristol-Myers Squibb, Cyberonics, Eli Lilly,
Forest Laboratories/Parke-Davis, Glaxo Wellcome, Janssen, Novartis, Organon,
Pfizer, Pharmacia - Upjohn, SmithKline Beecham, Wyeth - Ayerst, and Zeneca. He has
served as a consultant to Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest
Laboratories/Parke-Davis, Glaxo Wellcome, Janssen, Merck, Organon, Pfizer,
Pharmacia - Upjohn, and Wyeth - Ayerst. He has been a member of speakers'
bureaus sponsored by Abbott, Bristol-Myers Squibb, Cyberonics, Eli Lilly,
Forest Laboratories/Parke-Davis, Glaxo Wellcome, Organon, Pfizer, Pharmacia -
Upjohn, and Wyeth - Ayerst. Dr. Schatzberg has served as a consultant to or
received honorariums from Abbott, Bristol-Myers Squibb, Corcept Therapeutics,
Forest Laboratories, Janssen, Eli Lilly, Merck, Mitsubishi Pharmaceuticals,
Organon, Parke-Davis, Pfizer, Pharmacia - Upjohn, Sanofi, Scirex, SmithKline
Beecham, Solvay, and Wyeth - Ayerst. He has received research support from Bristol-Myers
Squibb, Pfizer, and SmithKline Beecham. He has equity ownership in Corcept,
Merck, Pfizer, and Scirex.
<CENTER
Medical Monopoly Information
The Medical Monopoly:
Protecting Consumers or Limiting Competition? Sue A. Blevins
The
Medical Monopoly: Your Tax Dollars Limit the Competition by Richard Leviton
Patient Power (How the
Cost-Plus System Evolved)
Back
to main Vaccine Dangers Page
Please
call, write or email for more detailed information snakken@nccn.net
Back to Top
ALL INFORMATION, DATA, AND MATERIAL
CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY
AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE
PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL
ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.